Can NLRP3 inflammasome inhibition modify disease progression in symptomatic AD patients?

immunology open composite 72%
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
72%
Novelty
80%
Mechanistic
—
Druggability
—
Priority
79%
Importance
92%
Tractability
85%
Market price
50%

Description

While NLRP3 ranked highest for therapeutic potential, the debate noted most targets are only tested in prevention paradigms. Whether inflammasome pathways remain actionable after symptom onset is critical for clinical translation.

Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d (Analysis: SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d)